Medicinal Chemistry of Neglected Tropical Diseases: Advances in the Design and Synthesis of Antimicrobial Agents
暫譯: 被忽視熱帶疾病的藥物化學：抗微生物劑的設計與合成進展

《被忽視的熱帶疾病藥物化學：抗微生物劑的設計與合成進展》整合並描述了當前用於識別有效化療藥物以治療被忽視的熱帶疾病（NTDs）的現代藥物發現與開發方法，從藥物化學的角度出發。各章節旨在滿足從事NTDs化療開發的藥物化學家的需求，同時也為希望在此領域工作的初學藥物化學家提供指導。書中將介紹在設計化療藥物時所採用的理性藥物設計方法以及可用於此目的的經過驗證的靶點。

Venkatesan Jayaprakash is working as Associate Professor in the Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi-835215, Jharkhand, India. He got his Bachelor of Pharmacy degree from Madras Medical College, Chennai, India and Master of Pharmacy degree form Banaras Hindu University, Varanasi, India. He obtained his PhD in Pharmacy from Birla Institute of Technology, Mesra, India in the area of Antitubercular Drug Design.

Medicinal Chemistry and Organic synthesis of Small molecule heterocyclic compounds against communicable diseases is the focus area of his research. He is in collaboration with leading biologists around the world for his research in the area of Tuberculosis, Dengue and Chikungunya. He has around fifty publications to his credit. He has also handled two Indo-German and an Indo-UK collaborative research projects. Currently he is working in the area of Antitubercular Drug Design exploring the enzymes in the biosynthesis of Mycobactin. A chapter in this book is also dedicated to the drug design approaches in the inhibition of Mycobactin biosynthesis.

He has supervised four PhD scholars along with Dr. Barij Nayan Sinha and is currently supervising two Research Scholars in the area of Tuberculosis and Dengue. He also supervised the theses of around twenty M. Pharmacy graduates. He is serving as Editor for Journal of Pharmaceutical Chemistry and acted as Member of Editorial Board of PharmBIT, an official journal published by Pharmaceutical Society of Department of Pharmaceutical Sciences & Technology, BIT, Mesra.

Dr. Daniele Castagnolo obtained his Ph.D. in Medicinal Chemistry and Pharmaceutical Sciences at the University of Siena (Italy) in December 2006 working with Professor Maurizio Botta on the design and synthesis of anti-mycobacterial agents exploiting in-silico approaches (ligand -based virtual screening). After completing his Ph.D., Dr. Castagnolo carried out his postdoctoral studies at the Helsinki University of Technology (Finland), the University of Siena as Research Fellow, and the University of Manchester (UK). In November 2012, Dr. Castagnolo joined Northumbria University Newcastle as a lecturer and he started his independent research activity. Finally, in September 2015, Daniele moved to King's College London, at the Institute of Pharmaceutical Science, where he is currently lecturer of pharmaceutical chemistry. The main research activity of Dr. Castagnolo is represented by the design, synthesis and identification of novel active pharmaceutical ingredients (APIs) for the treatment of bacterial and viral infections. In particular, Dr. Castagnolo has a solid background in the repurposing and optimization of mislaid and abandoned drugs to accelerate the discovery and development of more efficient and broad(er)-spectrum treatments against drug-resistant tuberculosis and re-emerging and neglected viral infections. Finally, Dr. Castagnolo is also working on the development of novel and sustainable and "green" (bio)-catalytic processes for the manufacturing of heterocyclic drugs.

Dr. Castagnolo research group consists of 2 PhD students, 2 Postdoctoral Research Assistants and 3 MPharm students. Daniele has a solid experience in the supervision of postgraduate students. The research activity of Dr. Castagnolo is described in 44 interdisciplinary pharmaceutical/chemistry international peer-reviewed papers and 2 book chapters including recent articles in Journal of Medicinal Chemistry, Chemical Communications, ACS-Catalysis. DC works obtained 817 citations (h-index = 16, i10-index = 25).

Dr. Castagnolo has secured external funding to support his research from EPSRC (Global Challenge KCL Internal Competition and Strategic Research Fund), BBSRC (i-case studentship in collaboration with Prozomix Ltd), Royal Society of Chemistry (Research fund 2015 and Undergraduate Research Bursary 2015), the BSAS (KTN Scholarship) and Northumbria University (fully funded PhD Studentship). DC is member of the COST Action CM1303 Systems Biocatalysis, MC member of the COST Action CM1207GLISTEN and MRSC member of the Royal Society of Chemistry. DC is Scientific Advisor for www.lifescienceevents.com.

Yusuf Özkay is working as an Associate Professor in the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey. He graduated from Faculty of Pharmacy, Anadolu University in 2003 and remained at Anadolu University Faculty of Pharmacy to complete his Master of Science in 2005 and PhD degree in 2009. He received the Associate Professor degree in 2011. His current research interests are synthesis of new compounds such as antimicrobial, anticancer, cholinesterase inhibitor, monoamine oxidase inhibitor and cycloxygenase inhibitor candidates. He has worked on nearly 30 projects on pharmacology evaluation of newly synthesized compounds. He has directed 8 projects in this area. He has about 40 publications in reputed journals, book chapters, about 70 presentations, 3 national university and 1 drug industry scientific awards. He is the vice dean of Anadolu University Faculty of Pharmacy since April 2013.

Venkatesan Jayaprakash 目前擔任印度賈坎德邦梅斯拉比爾拉科技學院藥學與技術系的副教授。他在印度金奈的馬德拉斯醫學院獲得藥學學士學位，並在印度瓦拉納西的班納拉斯印度大學獲得藥學碩士學位。他在印度梅斯拉的比爾拉科技學院獲得藥學博士學位，研究主題為抗結核藥物設計。

他的研究重點是針對傳染病的小分子雜環化合物的藥物化學和有機合成。他與全球領先的生物學家合作，研究結核病、登革熱和基孔肯雅熱。他擁有約五十篇的學術出版物，並曾負責兩個印德合作及一個印英合作的研究項目。目前，他正在研究抗結核藥物設計，探索在 Mycobactin 生物合成中的酶。這本書中有一章專門介紹 Mycobactin 生物合成抑制的藥物設計方法。

他與 Dr. Barij Nayan Sinha 一起指導了四位博士生，並目前指導兩位研究學者，專注於結核病和登革熱的研究。他還指導了約二十位藥學碩士畢業生的論文。他擔任《藥物化學期刊》的編輯，並曾擔任比爾拉科技學院藥學與技術系官方期刊 PharmBIT 的編輯委員會成員。

Dr. Daniele Castagnolo 於2006年12月在意大利錫耶納大學獲得藥物化學和藥學的博士學位，研究主題為利用 in-silico 方法（基於配體的虛擬篩選）設計和合成抗分枝桿菌劑，指導教授為 Maurizio Botta。完成博士學位後，Dr. Castagnolo 在芬蘭赫爾辛基科技大學、錫耶納大學擔任研究員，以及英國曼徹斯特大學進行博士後研究。2012年11月，Dr. Castagnolo 加入英國諾森比亞大學紐卡斯爾校區擔任講師，並開始獨立的研究活動。最終，在2015年9月，Daniele 轉至倫敦國王學院的藥學研究所，目前擔任藥物化學講師。Dr. Castagnolo 的主要研究活動是設計、合成和鑑定新型活性藥物成分（APIs），用於治療細菌和病毒感染。特別是，Dr. Castagnolo 在重新利用和優化被遺棄的藥物方面具有扎實的背景，以加速對抗耐藥性結核病和重新出現及被忽視的病毒感染的更有效和更廣泛的治療的發現和開發。最後，Dr. Castagnolo 也在開發新型、可持續和“綠色”的（生物）催化過程，用於雜環藥物的製造。

Dr. Castagnolo 的研究團隊由2名博士生、2名博士後研究助理和3名藥學碩士生組成。Daniele 在指導研究生方面擁有豐富的經驗。Dr. Castagnolo 的研究活動已在44篇跨學科的藥學/化學國際同行評審論文和2章書中描述，包括最近在《藥物化學期刊》、《化學通訊》和《ACS催化》上的文章。DC 的研究成果獲得了 817 次引用（h-index = 16, i10-index = 25）。

Dr. Castagnolo 獲得了來自 EPSRC（全球挑戰 KCL 內部競賽和戰略研究基金）、BBSRC（與 Prozomix Ltd 合作的 i-case 學生獎學金）、皇家化學學會（2015年研究基金和2015年本科生研究獎學金）、BSAS（KTN 獎學金）和諾森比亞大學（全額資助的博士生獎學金）的外部資金以支持他的研究。DC 是 COST 行動 CM1303 系統生物催化的成員，COST 行動 CM1207GLISTEN 的 MC 成員，以及皇家化學學會的 MRSC 成員。DC 是 www.lifescienceevents.com 的科學顧問。

Yusuf Özkay 目前擔任土耳其埃斯基謝希爾安納多盧大學藥物化學系的副教授。他於2003年從安納多盧大學藥學院畢業，並在該校完成了2005年的碩士學位和2009年的博士學位。他於2011年獲得副教授資格。他目前的研究興趣包括合成新化合物，如抗微生物、抗癌、膽鹼酯酶抑制劑、單胺氧化酶抑制劑和環氧合酶抑制劑候選物。他參與了近30個新合成化合物的藥理評估項目，並指導了8個相關項目。他在知名期刊上發表了約40篇論文、書章，並進行了約70次報告，獲得了3項國家大學和1項藥品行業的科學獎項。自2013年4月以來，他一直擔任安納多盧大學藥學院的副院長。